Following non-submission
AWMSG advice |
||
| Status: Not endorsed (Statement of Advice) | ||
In the absence of a submission from the holder of the marketing authorisation, ramucirumab (Cyramza®) cannot be endorsed for use within NHS Wales as monotherapy for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma who have a serum alpha fetoprotein ≥ 400 ng/mL and who have been previously treated with sorafenib |
||
|
||
Medicine details |
||
| Medicine name | ramucirumab (Cyramza®) | |
| Formulation | 10 mg/ml concentrate for solution for infusion | |
| Reference number | 2141 | |
| Indication | For use as monotherapy for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma who have a serum alpha fetoprotein ≥ 400 ng/mL and who have been previously treated with sorafenib |
|
| Company | Eli Lilly & Co Ltd | |
| BNF chapter | Malignant disease & immunosuppression | |
| Assessment type | Non-submission | |
| Status | Not endorsed (Statement of Advice) | |
| Ratification by Welsh Government | 28/11/2019 | |
| Date of issue | 29/11/2019 | |